Resolving the Combinatorial Complexity of Smad Protein Complex Formation and Its Link to Gene Expression
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Upon stimulation of cells with transforming growth factor β (TGF-β), Smad proteins form trimeric complexes and activate a broad spectrum of target genes. It remains unresolved which of the possible Smad complexes are formed in cellular contexts and how these contribute to gene expression. By combining quantitative mass spectrometry with a computational selection strategy, we predict and provide experimental evidence for the three most relevant Smad complexes in the mouse hepatoma cell line Hepa1-6. Utilizing dynamic pathway modeling, we specify the contribution of each Smad complex to the expression of representative Smad target genes, and show that these contributions are conserved in human hepatoma cell lines and primary hepatocytes. We predict, based on gene expression data of patient samples, increased amounts of Smad2/3/4 proteins and Smad2 phosphorylation as hallmarks of hepatocellular carcinoma and experimentally verify this prediction. Our findings demonstrate that modeling approaches can disentangle the complexity of transcription factor complex formation and its impact on gene expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS
Feng, X.-H., & Derynck, R. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.022404.142018 · Cited by 1,869
Raue, A., Kreutz, C., Maiwald, T., Bachmann, J., Schilling, M., Klingmüller, U., & Timmer, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp358 · Cited by 1,442 · cited 1×
“For statistical assessment, we calculated the profile likelihoods for the ten kon parameters of the considered trimeric Smad complexes (Raue et al., 2009), indicating the parameter ranges that are compatible with the experimental data.”
MethodSelf-citationAlterations in components of the TGF-β superfamily signaling pathways in human cancer
LEVY, L., & HILL, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.009 · Cited by 539 · cited 1×
“Numerous intragenic mutations and homozygous deletions of Smad2 and Smad4, as well as downregulation of Smad3 mRNA, were reported for different forms of carcinoma (Levy and Hill, 2006).”
BackgroundT160-phosphorylated CDK2 defines threshold for HGF-dependent proliferation in primary hepatocytes
Mueller, S., Huard, J., Waldow, K., Huang, X., D'Alessandro, L. A., Bohl, S., Börner, K., Grimm, D., Klamt, S., Klingmüller, U., et al. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156032 · Cited by 23
Self-citation
Cited by
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Tzavlaki, K., & Moustakas, A. (2020) · Biomolecules · doi:10.3390/biom10030487 · Cited by 796
Specificity, versatility, and control of TGF-β family signaling
Derynck, R., & Budi, E. H. (2019) · Science Signaling · doi:10.1126/scisignal.aav5183 · Cited by 785
Chen, L., Yang, T., Lu, D.-W., Zhao, H., Feng, Y.-L., Chen, H., Chen, D.-Q., Vaziri, N. D., & Zhao, Y.-Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.090 · Cited by 359
JNK regulates muscle remodeling via myostatin/SMAD inhibition
Lessard, S. J., MacDonald, T. L., Pathak, P., Han, M. S., Coffey, V. G., Edge, J., Rivas, D. A., Hirshman, M. F., Davis, R. J., & Goodyear, L. J. (2018) · Nature Communications · doi:10.1038/s41467-018-05439-3 · Cited by 119
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Haga, M., Iida, K., & Okada, M. (2024) · iScience · doi:10.1016/j.isci.2024.109708 · Cited by 19
Propolis compound inhibits profibrotic TGF-β1/SMAD signalling in human fibroblasts
Randall, L. J., Bajan, S., Tran, T. D., Harvey, R. J., & Russell, F. D. (2025) · Scientific Reports · doi:10.1038/s41598-025-07918-2 · Cited by 9
“Notably, redundancy may exist for SMAD signalling, with evidence for the formation of SMAD3-independent complexes in cells that have been exposed to TGF-β1, for example, the formation of a SMAD2/4/4 complex 37 .”
Konrath, F., Willenbrock, M., Busse, D., Scheidereit, C., & Wolf, J. (2023) · iScience · doi:10.1016/j.isci.2023.107917 · Cited by 7
Transcriptional regulators ensuring specific gene expression and decision-making at high TGFβ doses
Hartmann, L., Kristofori, P., Li, C., Becker, K., Hexemer, L., Bohn, S., Lenhardt, S., Weiss, S., Voss, B., Loewer, A., et al. (2025) · Life Science Alliance · doi:10.26508/lsa.202402859 · Cited by 4
Metadata
- Authors
- Lucarelli, P., Schilling, M., Kreutz, C., Vlasov, A., Boehm, M. E., Iwamoto, N., Steiert, B., Lattermann, S., Wäsch, M., Stepath, M., Matter, M. S., Heikenwälder, M., Hoffmann, K., Deharde, D., Damm, G., Seehofer, D., Muciek, M., Gretz, N., Lehmann, W. D., Timmer, J., & Klingmüller, U.
- Venue
- Cell Systems
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 6
- Issue
- 1
- Pages
- 75-89.e11
- ISSN
- 2405-4712 (ISSN-L)
- OpenAlex
- W2774296853
- Cited by
- 60
- References
- 4
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.